EUVIMEDEUVIMED entdecken
Crossref

Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors’ Binding Pocket

Fabao Zhao, Heng Zhang, Minghui Xie, Bairu Meng, Na Liu, Caiyun Dun, Yanyang Qin, Shenghua Gao, Erik De Clercq iD, Christophe Pannecouque, Ya-Jie Tang iD, Peng Zhan iD und 2 weitere

Journal of Medicinal Chemistry · 09.02.2023 · 66 (3) · 2102-2115

DOI: 10.1021/acs.jmedchem.2c01875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.01.2023. Verfasst von Fabao Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of …. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Taishan Scholar Project of Shandong Province, Shandong University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although non-nucleoside reverse transcriptase inhibitors (NNRTIs) exhibit potent anti-HIV-1 activity and play an important role in the active antiretroviral therapy of AIDS, the emergence of drug-resistant strains has seriously reduced their clinical efficacy. Here, we report a series of 2,4,5-trisubstituted pyrimidines as potent HIV-1 NNRTIs by exploiting the tolerant regions of the NNRTI binding pocket. Compounds 16b and 16c were demonstrated to have excellent activity (EC50 = 3.14-22.1 nM) against wild-type and a panel of mutant HIV-1 strains, being much superior to that of etravirine (EC50 = 3.53-52.2 nM). Molecular modeling studies were performed to illustrate the detailed interactions between RT and 16b, which shed light on the improvement of the drug resistance profiles. Moreover, 16b possessed favorable pharmacokinetic (T1/2 = 1.33 h, F = 31.8%) and safety profiles (LD50 > 2000 mg/kg), making it a promising anti-HIV-1 drug candidate for further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV-1Reverse Transcriptase InhibitorsStructure-Activity RelationshipHIV Reverse TranscriptasePyrimidinesDrug Design

Substanzen

Reverse Transcriptase InhibitorsHIV Reverse TranscriptaseAnti-HIV AgentsPyrimidines

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan 250012 Shan…
  • Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Herestraat 49 Postbus 1043 (09.A097), Leuven B-3000, Belgium.
  • State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China.
  • China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, 44 West Culture Road, Jinan 250012 Shandong, PR China.

ORCID-Profile: Erik De Clercq, Ya-Jie Tang, Peng Zhan, Xinyong Liu, Dongwei Kang

Förderung

  • Taishan Scholar Project of Shandong Province
  • Shandong University
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Zhao, F., Zhang, H., Xie, M., Meng, B., Liu, N., Dun, C., Qin, Y., Gao, S., De Clercq, E., Pannecouque, C., Tang, Y. J., Zhan, P., Liu, X., & Kang, D. (2023). Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors’ Binding Pocket. Journal of Medicinal Chemistry, 66(3), 2102-2115. https://doi.org/10.1021/acs.jmedchem.2c01875

Vancouver

Zhao F, Zhang H, Xie M, Meng B, Liu N, Dun C, et al. Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors’ Binding Pocket. Journal of Medicinal Chemistry. 2023;66(3):2102-2115. doi:10.1021/acs.jmedchem.2c01875

BibTeX
@article{Zhao2023,
  author = {Zhao, Fabao and Zhang, Heng and Xie, Minghui and Meng, Bairu and Liu, Na and Dun, Caiyun and Qin, Yanyang and Gao, Shenghua and De Clercq, Erik and Pannecouque, Christophe and Tang, Ya-Jie and Zhan, Peng and Liu, Xinyong and Kang, Dongwei},
  title = {Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors’ Binding Pocket},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {3},
  pages = {2102--2115},
  doi = {10.1021/acs.jmedchem.2c01875}
}
Kostenlos starten →